Inovio Pharmaceuticals (NASDAQ:INO) PT Lowered to $33.00 at Oppenheimer

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective cut by Oppenheimer from $40.00 to $33.00 in a report published on Monday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other analysts have also commented on INO. HC Wainwright reaffirmed a neutral rating and issued a $15.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. Stephens started coverage on Inovio Pharmaceuticals in a research note on Tuesday, May 14th. They issued an overweight rating and a $20.00 price objective on the stock. Finally, Royal Bank of Canada reduced their price objective on Inovio Pharmaceuticals from $11.00 to $8.00 and set a sector perform rating on the stock in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Hold and an average price target of $44.00.

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $7.82 on Monday. The stock’s fifty day simple moving average is $9.36 and its 200 day simple moving average is $9.81. The firm has a market cap of $202.62 million, a price-to-earnings ratio of -2.44 and a beta of 0.89. Inovio Pharmaceuticals has a one year low of $3.89 and a one year high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 88.13%. During the same period in the prior year, the firm earned ($1.56) EPS. On average, research analysts anticipate that Inovio Pharmaceuticals will post -4.5 earnings per share for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several large investors have recently made changes to their positions in INO. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 5.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 6,148 shares during the period. Keystone Financial Group lifted its stake in shares of Inovio Pharmaceuticals by 11.7% during the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 12,840 shares during the period. Signature Estate & Investment Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $88,000. Cornercap Investment Counsel Inc. acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $184,000. Finally, American Century Companies Inc. lifted its stake in shares of Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 12,100 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.